SCHEMBL17796641

SCHEMBL17796641

CC(C)(C(=O)N1CCOCC1)c1ccc(Cl)nc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.52
SMN1; SMN2 Q16637 4/20 0.49
RAB9A P51151 4/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
CYP11B2 P19099 1/20 0.42
NR1I2 O75469 1/20 0.42
KCNH2 Q12809 1/20 0.42
GRM2 Q14416 1/20 0.42
NPC1 O15118 2/20 0.41
HPGD P15428 1/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.40
FNTA P49354 1/20 0.40
FNTB P49356 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
LIPE Q05469 1/20 0.40
PHGDH O43175 1/20 0.39
FKBP1A P62942 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3401971 0.76 SMN1; SMN2 (0.55) AKR1C3SMN1; SMN2RAB9AALDH1A1GAA
SCHEMBL23089439 0.76 AKR1C3 (0.42) AKR1C3SMN1; SMN2ALDH1A1GAAMAPT
SCHEMBL29814641 0.76 AKR1C3 (0.42) AKR1C3SMN1; SMN2ALDH1A1GAAMAPT
SCHEMBL19070596 0.75 SMN1; SMN2 (0.77) AKR1C3SMN1; SMN2RAB9AHPGDPHGDH
SCHEMBL15023275 0.73 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AALDH1A1NR1I2KCNH2
SCHEMBL17796333 0.73 NAPRT (0.48) AKR1C3SMN1; SMN2RAB9AALDH1A1GAA
SCHEMBL2072292 0.73 SMN1; SMN2 (0.70) AKR1C3SMN1; SMN2RAB9AALDH1A1MAPT
SCHEMBL16464172 0.73 SMN1; SMN2 (0.55) SMN1; SMN2RAB9AALDH1A1NR1I2KCNH2
SCHEMBL29847257 0.72 BRS3 (0.44) SMN1; SMN2RAB9AALDH1A1GAANPC1
SCHEMBL3703753 0.72 BRS3 (0.44) SMN1; SMN2RAB9AALDH1A1GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
US-20160159773-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-09 US disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 EP disclosed
EP-3029031-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159773-A1 HETEROCYCLIC COMPOUND TYK2, SSB, UACA AKR1C3 3124/4885SMN1; SMN2 2576/4885RAB9A 2304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.